Chemical name: 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile;
Anabolic activity index: not a steroid
Androgenic activity index: not a steroid
LETROMINA 2.5mg – ALPHA PHARMA
Letromina is a non-steroidal aromatase inhibitor that is used to treat breast cancer in postmenopausal women. It is a medication that helps to reduce the levels of estrogen in the body, which is important in the treatment of hormone receptor positive breast cancer. Letromina is highly effective in preventing the recurrence of breast cancer and also reducing the risk of developing breast cancer in women who are at high risk for the disease.
One of the important characteristics of Letromina is its active half-life of 2 days. This means that the medication stays effective in the body for a period of time after it has been taken. The classification of Letromina as a non-steroidal aromatase inhibitor means that it does not contain any steroids, which can have significant side effects. The dosage of Letromina typically ranges from 0.5 to 2.5 mg per day, depending on the patient’s specific needs.
Another important characteristic of Letromina is that it does not cause acne or water retention, which are side effects associated with many other medications used in the treatment of breast cancer. Letromina is also not associated with hepatotoxicity, or liver damage, and does not cause aromatization, which is a process by which testosterone is converted into estrogen.
The active substance in Letromina is Letrozole, which is a potent aromatase inhibitor that works by inhibiting the conversion of androgens into estrogens. Letrozole is highly effective at reducing the levels of estrogen in the body and has been shown to be effective in treating breast cancer in postmenopausal women.
Letromina is available in the form of 30 pills x 2.5 mg and is manufactured by Alpha Pharma, a well-known pharmaceutical company with a reputation for producing high-quality medications. Overall, Letromina is a highly effective medication that is used to treat breast cancer in postmenopausal women and is associated with few side effects.